Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solubility, Polymorphism, Crystallinity, Crystal Habit, and Drying Scheme of (R, S)-(±)-Sodium Ibuprofen Dihydrate
The racemic compound (R, S)-(±)-ibuprofen is a popular and well understood active pharmaceutical ingredient, but it has several disadvantageous formulation properties such as poor solubility, low melting point, and potential esterification with excipients containing an hydroxyl group. The authors investigate the use of an (R, S)-(±)-ibuprofen salt to evaluate these problems using various analytical methods to determine the polymorphism, crystallinity, and drying scheme.


Pharmaceutical Technology



Figure 5
When the positions of the 23 solvents were located within the 3-D space of a dispersion-force component (δd), a polar component (δp), and a hydrogen-bonding component (δh) according to their corresponding coordinates of (δd, δp, δh, ) in Table I and all the good solvents were represented by yellow and bad solvents by red in the form space (see Table III), a cluster of yellow domains were formed. The contour of these yellow domains outlined a 3-D volume of solubility in space. Good solvents were those solvents within the volume, bad solvents were solvents outside the volume (see Figure 5). This space could be represented by a solubility sphere with center coordinates (δd,API, δp,API, δh,API) and interaction radius (RS-API), for (R, S)-(±)-sodium ibuprofen dihydrate in the 3-D Hansen plot.

By trial and error, the center coordinates (δd,API, δp,API, δh,API) were determined using the following (15):










Figure 6
in which DS–API was the distance between the solvent location and the center of the sphere. For the 23 solvents listed in Table I with their corresponding sets of Hansen parameters (δd,s, δp,s, δh,s ), 23 DS–API would result for any chosen set of center coordinates (δd,API, δp,API, δh,API). Only one particular set of center coordinates of (δd,API, δp,API, δh,API) giving 9 DS–API values for nine corresponding good solvents that were < the 14 DS–API values calculated from the 14 bad solvents. The largest value among the nine DS–API values was the interaction radius of the solubility sphere. For (R, S)-(±)-sodium ibuprofen dihydrate at 25 °C, the values of δd,API, δp,API, δh,API, and RS–API with respect to the 23 solvents listed in Table I were determined to be 19.89, 16.19, 30.89 and 25.92 MPa1/2, respectively (21, 22).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here